Anvisa opened Public Consultation No. 311 of February 15, 2017 for contributions by the company to the text that will serve as the basis for the proposed revision of RDC 54/2013, which regulates the implementation of the National Drug Control System. In practice, this means drafting the guidelines for the traceability of medicines in the pharmaceutical chain. Those interested in contributing have, as of today, the date on which the opening of the CP was published in the Official Gazette of the Union, 30 days to send their comments and suggestions.
Anvisa’s CEO Jarbas Barbosa celebrates the initiative: “This RDC draft that was approved by the Collegiate Board to go to the Public Consultation is the result of a process of technical maturity within the Agency and a broad dialogue with all sectors Involved. The RDC will receive new contributions and will enable, after its final approval, the effective implementation of the National Drug Control System “